Human Papillomavirus Vaccine Administration Among Medicaid Providers Who Consistently Recommended Vaccination

Malo, Teri L. PhD*; Staras, Stephanie A. S. PhD; Bynum, Shalanda A. PhD; Giuliano, Anna R. PhD§¶∥; Shenkman, Elizabeth A. PhD; Vadaparampil, Susan T. PhD*¶∥

Sexually Transmitted Diseases: January 2014 - Volume 41 - Issue 1 - p 24–28
doi: 10.1097/OLQ.0000000000000064
Note

Abstract: We examined factors potentially related to providers’ self-reported human papillomavirus vaccine administration to female Medicaid enrollees among providers who consistently recommended vaccination. Some pronounced variability was observed in characteristics among providers who consistently administered vaccination, including provider age, race, and Vaccines for Children enrollment; patient/parent vaccine refusal; patient race/ethnicity; and patient volume.

Provider age, race, and Vaccines for Children enrollment; patient/parent vaccine refusal; patient race/ethnicity; and patient volume may be related to human papillomavirus vaccine administration among providers who consistently recommended vaccination.

From the *Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, FL; †Department of Health Outcomes and Policy, College of Medicine, and the Institute for Child Health Policy, University of Florida,Gainesville, FL; ‡Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD; §Cancer Epidemiology Program and ¶Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL; and ∥Department of Oncologic Science, College of Medicine, University of South Florida, Tampa, FL

The work contained within this publication was supported in part by the Survey Methods Core Facility at the Moffitt Cancer Center. The authors thank Deepa Ranka, MS, and the Medicaid programming team at the Institute for Child Health Policy for sample selection and data management.

Regarding potential conflicts of interest, Dr Giuliano has received funding from Merck for consultancy and lectures. In addition, she receives grant funding from Merck and GlaxoSmithKline. For the remaining authors, no conflicts were declared.

This research was supported by grants from the University of Florida (UF09035) and the National Institutes of Health (NIH; R01AI076440-01). Drs. Staras and Shenkman were supported in partby NIH/National Center for Research Resources Clinical and Translational Science Awards award to the University of Florida (UL1 RR029890). Dr Staras also was supported in part by the NIH (K01 AA018255).

Correspondence: Susan T. Vadaparampil, PhD, Moffitt Cancer Center, 12902 Magnolia Dr, MRC-CANCONT, Tampa, FL 33612. E-mail: Susan.Vadaparampil@moffitt.org.

Received for publication April 19, 2013, and accepted October 18, 2013.

© Copyright 2014 American Sexually Transmitted Diseases Association